Theo Melas-Kyriazi

Theo Melas-Kyriazi joined Flagship as executive partner in April 2019. Prior to joining Flagship as executive partner, Theo was chief financial officer of Levitronix Technologies LLC, a leader in magnetically levitated pumps for microelectronics and bioprocessing applications. He spent nearly two decades at Thermo Electron Corporation (now Thermo Fisher Scientific) in a variety of roles, including six years as CFO. Theo has been a director of several private and public biopharmaceutical companies. Across the course of these roles, Theo raised $2B in equity and convertible debt; executed 5 IPOs of Thermo Fisher Scientific’s subsidiary companies; grew one subsidiary from $40M to $200M in revenues over four years; and executed a broad restructuring that transformed a $4B diversified holding company into a $2B company focused on serving life science customers, among other accomplishments.

Over the last 20 years, Theo has served on the boards of multiple public and private healthcare and life science companies, including Valeant Pharmaceuticals, Thoratec Corporation, Helicos, and Moderna (NASDAQ: MRNA). Theo currently serves on the boards of the following Flagship companies: Evelo Biosciences, Codiak Biosciences, Cygnal Therapeutics, Kaleido Biosciences, and KSQ Therapeutics. He also served as an operating partner of a middle-market private equity firm from 2007 to 2012.

Theo holds a bachelor’s degree in economics and an M.B.A from Harvard University.